Tesofensine
A triple monoamine reuptake inhibitor originally developed for neurodegenerative disease, later found in Phase 2 obesity trials to produce substantial appetite suppression.
Research status: Phase 2 data only; not FDA-approved for weight management.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
Related in Weight Loss